Share this article
Share this article
ResearchAndMarkets.com s offering.
The global market for CNS Therapeutics is projected to reach US$137.7 billion by 2025, driven by the urgent need to address the unmet medical needs of neurological disorders. Diseases of the brain and mind range from epilepsy, stroke, migraine, Alzheimer`s, Parkinson`s, dementia, multiple sclerosis, brain injuries, neuroinfections, schizophrenia, psychosis and other mental disorders. With unmet needs continuing to persist, societal and healthcare burden continues to increase.
Stroke and infections such as meningitis and encephalitis continue to be the leading cause of disability worldwide, pushing up the cost of nursing care, hospice and bringing down quality of life. The unmet needs are evident in all phases of drug development i.e. identification of therapeutic targets; optimization of lead compounds; gaps in toxicity and pharmacokinetics studies; and slow resolution of ethical issues, among others. The n
Press release content from Business Wire. The AP news staff was not involved in its creation.
New Genentech Data at 2021 AAN Highlight Impact and Breadth of Expanding Neuroscience Portfolio
April 8, 2021 GMT
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) Apr 8, 2021
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually April 17-22, 2021. These new data include 23 abstracts highlighting the expanding Genentech neuroscience portfolio across six therapeutic areas, including Evrysdi™ (risdiplam) for spinal muscular atrophy (SMA), Ocrevus ® (ocrelizumab) in relapsing and primary progressive multiple sclerosis (RMS and PPMS), investigational Bruton’s tyrosine kinase inhibitor (BTKi) fenebrutinib in Phase III trials for RMS and PPMS, Enspryng™ (sat
(0)
EVRYSDI 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy (SMA)
OCREVUS data show its consistent benefit on slowing disease progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS)
Data for ENSPRYNG in neuromyelitis optica spectrum disorder (NMOSD) reinforce safety and efficacy, including in patients with concomitant autoimmune diseases (CAIDs)
Data for investigational MS medicine fenebrutinib support its safety profile and high potency
Additional presentations on investigational programmes, including Alzheimer s disease and Huntington s disease, help advance scientific understanding of neurological disorders
Basel, 8 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data for its approved and investigational medicines for the treatment of neurological disorders will be presented at the 73rd American Academy of Neurology (AAN) Annual Meeting being held virtually Apr
ip
eline drugs in the Primary Progressive Multiple Sclerosis pipeline landscapes. It comprises PPMS pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Primary Progressive Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive PPMS pipeline products.
Some of the crucial features of the Primary Progressive Multiple Sclerosis key players such as
Atara Biotherapeutics, MediciNova, AB Science, and many others involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Different therapeutic candidates are segmented into early-stage, mid-stage, and late-stage of development for the PPMS treatment.